

# CHONDROSARCOMA FOUNDATION THINK TANK

Tuesday, November 11, 8:30AM – 2:30PM

Doubletree Hotel, Deerfield Beach – Boca Raton, Florida



CHONDROSARCOMA  
FOUNDATION

## Advancing Chondrosarcoma Treatment Challenge #1: Preventing Disease Progression, Recurrence & Metastasis

An interactive, one-day meeting to unite clinicians, researchers, industry, patients, and advocates to address how we can collectively advance precision medicine and treatment for chondrosarcoma. The product of the think tank would be a meeting summary to support a strategic plan for the Chondrosarcoma Foundation to obtain and build resources that will advance the prevention of disease progression and advance effective care.

Please visit [csfshayna.org/thinktank](http://csfshayna.org/thinktank) to register & view the itinerary and hotel information.

### Topic 1: Introductions / Overview

A review of research, clinical trials, and medical practice efforts to address chondrosarcoma and prevent disease progression.

- **Chair: William Tap, M.D.** Chief of Sarcoma Medical Oncology Service at Memorial Sloan Kettering Cancer Center in New York City

### Topic 2: Early Detection

An examination of efforts to address early detection of chondrosarcoma and a discussion of the benefit of developing and disseminating screening tools and use of other tests to the public and greater medical community.

- **Anthony P. Conley, M.D.**, is the Associate Professor of the Department of Sarcoma Medical Oncology, Division of Cancer Medicine at the University of Texas MD Anderson Cancer Center in Houston, TX.
- **John Gross, MD**, is a Faculty Assistant professor, bone and soft tissue, surgical pathology at Johns Hopkins University, Baltimore, Md.
- **Joseph H. Schwab, MD, MS**, Director of Spine Oncology for Orthopedic Surgery and Director of the Cedars-Sinai Center for Surgical Innovation and Engineering, Los Angeles, CA

### Topic 3: Diagnosis

A discussion of efforts to improve diagnosis, reduce misdiagnosis as well as discussing the role of genomic sequencing and AI can have in improving diagnosis and preventing disease progression.

- **John Gross, MD**, is a Faculty Assistant professor, bone and soft tissue, surgical pathology at Johns Hopkins University, Baltimore, Md.
- **Adrienne Flannagan, M.D.**, Professor of Musculoskeletal Pathology, Research Department of Pathology, University College London, UK

### Topic 4: Surgery and Interventions

Should surgery continue to be the first intervention considered in treating chondrosarcoma or do we consider other interventions or combinations before or immediately after surgery to prevent disease recurrence/metastasis?

- **Joseph H. Schwab, MD, MS**, Director of Spine Oncology for Orthopedic Surgery and Director of the Cedars-Sinai Center for Surgical Innovation and Engineering, Los Angeles, CA
- **Christian Meyer, M.D., Ph.D.** is the Assistant Professor and lead medical oncologist for adult sarcoma patients at Johns Hopkins Univ in Baltimore, Md.
- **J.W. Snider, M.D.**, Radiation Oncologist, Chief Medical Officer, Proton International, LLC; Delray Beach, FL

### Topic 5: Research, Clinical Trials, and Treatment Innovations

Looking at the status of chondrosarcoma research, clinical trials, and recommendations for innovative studies to prevent recurrence and metastasis. Examine the role of IDH1 and understand the difference between IDH1 mutated and nonmutated tumors and the progression genomically and epigenetically for both.

- **Jonathan C. Trent, M.D.**, is the Associate Director of Clinical Research and Director of the Bone and Soft-tissue Sarcoma Group, for the Sylvester Cancer Center, Miami, FL
- **William Cross, Ph.D.**, Director Rare Malignancies and Cancer Evolution laboratory, Reading University, Reading, UK
- **Adrienne Flannagan, M.D.**, Professor of Musculoskeletal Pathology, Research Department of Pathology, University College London, UK
- **Sant Chawla**, Chief Medical Director, Sarcoma Oncology Research Center, Santa Monica, CA

### Topic 6: Moving Forward

What can we do collectively to create a comprehensive strategy to prevent disease progression recurrence and metastasis?

- **Jonathan C. Trent, M.D.**, is the Associate Director of Clinical Research and Director of the Bone and Soft-tissue Sarcoma Group, for the Sylvester Cancer Center, Miami, FL
- **Neal Chawla, M.D.**, Medical Director, Sarcoma Oncology Research Center, Santa Monica, CA
- **Anthony P. Conley, M.D.**, is the Associate Professor of the Department of Sarcoma Medical Oncology, Division of Cancer Medicine at the University of Texas MD Anderson Cancer Center in Houston, TX.
- **Joseph H. Schwab, MD, MS**, Director of Spine Oncology for Orthopedic Surgery and Director of the Cedars-Sinai Center for Surgical Innovation and Engineering, Los Angeles, CA

### Closing Remarks

A summary and action items that we gathered through the day.

- **Chair: William Tap, M.D.** Chief of Sarcoma Medical Oncology Service at Memorial Sloan Kettering Cancer Center, New York

## SPONSORS

